MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Identifying therapeutic targets from spontaneous beneficial brain lesions

    J. Joutsa, L. Shih, A. Horn, M. Reich, J. Hsu, O. Wu, N. Rost, M. Fox (Charlestown, MA, USA)

    Objective: To determine whether rare cases in which spontaneously occurring brain lesions improved tremor can be used to identify a therapeutic target. Background: The search…
  • 2018 International Congress

    Diencephalic mesencephalic junction abnormalities in adult-onset movement disorders

    A.M. Crespo Cuevas, V. Puente, S. Medrano, L. Planellas, D. Vilas (Barcelona, Spain)

    Objective: To describe two cases of adult-onset movement disorders with diencephalic-mesencephalic junction dysplasia(DMJD). Background: DMJD is a rare malformation characterized by a poorly defined junction…
  • 2018 International Congress

    Role of metformin in diabetic aging female rat brain: a future therapy for neurodegenerative diseases

    P. Kumar, N. Baquer (New Delhi, India)

    Objective: The objective of this study was to investigate effects of metformin on glucose transporter (GLUT1, GLUT3) expression, intracellular calcium levels, expression of synaptic molecules…
  • 2018 International Congress

    Age related changes of cortical effective connectivity during bimanual motor control

    P. Loehrer, F. Nettersheim, I. Weber, F. Jung, L. Timmermann (Marburg, Germany)

    Objective: To identify age-related changes of bimanual coordination and characterize the underlying alterations of effective connectivity within the cortical motor system. Background: Exact signal processing…
  • 2018 International Congress

    Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

    V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

    Objective: This post-hoc analysis examined safinamide efficacy for providing dyskinesia-free ON time in LID patients. Background: Safinamide has both dopaminergic and glutamate modulating activity. The…
  • 2018 International Congress

    Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: The BIPARK-I double-blind experience

    J. Kulisevsky, E. Tolosa, J. Ferreira, A. Lees, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

    Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a novel once-daily COMT inhibitor,…
  • 2018 International Congress

    Effect of dual task as rehabilitation therapy in Parkinson’s disease in the UPDRS III

    C. Mejia (Lima, Peru)

    Objective: To determine the effect of the dual task used as Rehabilitation therapy in the UPDRS III of patients with Parkinson's disease. Background: Parkinson's disease…
  • 2018 International Congress

    Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience

    R.N. Taddei, V. Leta, A. Sauerbier, M. Parry, A. Podlewska, L. Hall, S. Tentis, P. Odin, W. Poewe, P. Dubois, D. van Warmelen, E.W. Lim, K.R. Chaudhuri (London, United Kingdom)

    Objective: To explore if catechol-O-methyl-transferase inhibition (COMT-I) can prolong the efficacy of daytime intrajejunal Levodopa infusion (IJLI) in Parkinson’s disease (PD) along with a reduction…
  • 2018 International Congress

    A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID

    D. Charvin, T. Di Paolo, E. Bezard, L. Gregoire, A. Takano, G. Duvey, E. Pioli, C. Halldin, R. Medori, F. Conquet (Plan-les-Ouates, Switzerland)

    Objective: Objective was to assess the therapeutic potential of our novel mGlu4 positive allosteric modulator (PAM), foliglurax, as an anti-parkinsonian treatment in gold-standard primate models.…
  • 2018 International Congress

    Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: NMSS analysis from the BIPARK-I double-blind experience

    A. Antonini, J. Ferreira, W. Poewe, O. Rascol, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a new once-daily COMT…
  • « Previous Page
  • 1
  • …
  • 148
  • 149
  • 150
  • 151
  • 152
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley